Overview STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders Status: Completed Trial end date: 2013-02-01 Target enrollment: Participant gender: Summary The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies. Phase: Phase 1 Details Lead Sponsor: Synta Pharmaceuticals Corp.